Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-05-30
2006-05-30
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388260, C530S388800
Reexamination Certificate
active
07053188
ABSTRACT:
Compositions and methods for diagnosis of neoplastic tissue are described. Monoclonal antibodies which specifically recognize the tumor cell specific NADH:protein thiol reductase and the hybridoma cell lines which produce them are provided. Also provided are diagnostic and immunohistological assays for the identification of cells that are neoplastic.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4263279 (1981-04-01), Sela et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4366241 (1982-12-01), Tom et al.
patent: 4460561 (1984-07-01), Goldenberg
patent: 4624846 (1986-11-01), Goldenberg
patent: 4952394 (1990-08-01), Senter
patent: 4986979 (1991-01-01), Morgan, Jr. et al.
patent: 5037630 (1991-08-01), Fritzberg et al.
patent: 5089249 (1992-02-01), Fritzberg et al.
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5332567 (1994-07-01), Goldenberg
patent: 5541297 (1996-07-01), Hansen et al.
patent: 5569673 (1996-10-01), Morré et al.
patent: 5605810 (1997-02-01), Morré et al.
patent: 5716595 (1998-02-01), Goldenberg
patent: 6235280 (2001-05-01), Chatterjee et al.
patent: 6395276 (2002-05-01), Rybak et al.
patent: 6632431 (2003-10-01), Wu
patent: 95/26743 (1995-12-01), None
patent: 01/032673 (2001-10-01), None
Jain R. K. Scientific American, 271(1):58-65, Jul. 1994.
Dillman R. O. Annals of Internal Medicine, 111:592-603, 1989.
Weiner L. M. Seminars in Oncology, 26 (4 Suppl 12):41-50, Aug. 1999.
Dillman, R. O. Journal of Clinical Oncology, 12(7):1497-1515, 1994.
Freshney R. I. Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 3-4.
Dermer G. B. Bio/Technology, 12:320, Mar. 12, 1994.
Jessani et al. Proc. Natl. Acad. Sci, USA, 101(38):13756-13761, Sep. 21, 2004.
Cho et al. Proceedings of the American Association for Cancer Research 39: 347, 1998, abstract #2972.
FUNDAMENTAL IMMUNOLOGY 242, William E. Paul, M.D. ed., 3d ed. 1993.
Yantiri et al. Archives of Biochemistry and Biophysics 358(2): 336-342, 1998.
Campbell A. M. Monoclonal Antibody Technology, Chapter 1:1-32, 1984.
Bhattacharya-Chatterjee M. (2001) “The anti-idiotype vaccines for immunotherapy”;Curr. Opinion. Mol. Ther.Feb.;3(1):63-69.
Chang, K. et al.(1992) “Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium”;Cancer Research52:181-186.
Chang, K. et al. (1996) “Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers”;Proc. Natl. Acad. Sci. USA93:136-140.
Chang, K. et al. (1994) “Molecular Cloning and Expression of a cDNA Encoding a Protien Detected by the K1 Antibody from an Ovarian Carcinoma (OVCAR-3) Cell Line”;Int. J. Cancer57:90-97.
Cho, et al. (2002) “Monoclonal antibody to a cancer-specific and drug-responsive hydroquinine (NADH) oxidase from the sera of cancer patients”;Caancer Immunol. Immunother.51(3):121-129.
Chueh, P-J. et al. “A 33.5-kDa heat-and protease-resistant NADH oxidase inhibited by capsaicin from sera of cancer patients”; (Jun. 1997)Arch. Biochem. Biophys.342(1):38-47.
Dillman, R.O. (2001) “Monoclonal Antibodies in the Treatment of Malignancy: Basic Concepts and Recent Developments”;Cancer Invest.19(8):833-841.
Durrant et al. (2001) “Human anti-idotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses”;Int. J. Cancer1;92(3):414-420.
Harlow, et al. (1988) “Monoclonal Antibodies”; Cold Spring Harbor Chapter 6, pp. 148-155.
Kelker et al. (2001) “Cancer isoform of a tumor-associated cell surface NADH oxidase (tNOX) has properties of a prion”;BiochemistryJun. 26;40(25):7351-7354.
Morré, D.J. (1995) “NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea”;Biochim. Biophys. Acta1240:201-208.
Morré et al. (1995) “Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture”;Proc. Natl. Acad. Sci. USA92:1831-1835.
Morré et al. (1995) “Identification of antitumor sulfonylurea binding proteins of HeLa plasma membranes”;Biochim. Biophys. Acta1236:237-243.
Morré et al. (1995) “The antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes”;Biochim. Biophys. Acta1240:11-17.
Morré et al. (1996) “Antitumor sulfonylurea-inhibited NADH oxidase of cultured HeLa cells shed into media”;Biochim. Biophys. Acta1280:197-206.
Morré et al. (1996) “Capsaicin Inhibits Plasma Membrane NADH Oxidase and Growth of Human and Mouse Melanoma Lines”;Eur. J. Cancer32:1995-2003.
Morré et al. (1997) “NADH Oxidase Activity from Sera Altered by Capsaicin Is Widely Distrubted among Cancer Patients”;Arch Biochem. Biophys.342:224-230.
Morré et al. (1999) “Use of dipyridyl-dithio substrates to measure directly the protein disulfide-thiol interchange activity of the auxin stimulated NADH: protein disulfide reductase (NADH oxidase) of soybean plasma membranes”;Mol. Cell. Biochem.Oct;200(1-2):7-13.
Morré and Morré (1995) “Differential Response of the NADH Oxidase of Plasma Membranes of Rat Liver and Hapatoma and HeLa Cells to Thiol Regents”;J. Bioenerg. Biomemb.27:137-144.
Morré and Reust (1997) “A Circulating Form of NADH Oxidase Activity Responsive to the Antitumor Sulfonylurea N-4-(methylphenylsulfonyl)-N′-(4-chlorophenylurea (LY181984) Specific to Sera from Cancer Patients”;J. Biomemb. Bioenerg.29:281-289.
Paulik et al. (1999) “Drug-antibody conjugates with anti-HIV activity”;Biochem. Pharmacol.Dec. 1;58(11):1781-1790.
Wilkinson et al. (1996) “Isolation and Identification of a Protein with Capsaicin-Inhibited NADH Oxidase Activity from Culture Medic Conditioned by Growth of HeLa Cells”;Arch. Biochem. Biophys.336:275-282.
Yantiri and Morré (2001) “Isolation and characterization of a tumor-associated NADH oxidase (tNOX) from the HeLa cell surface”;Arch Biochem. Biophys.Jul. 15:391(2):149-159.
Chueh Pin-Ju
McCarty NaMi
Morre D. James
Morré Dorothy
Blanchard David J.
Greenlee Winner & Sullivan, P.C.
Helms Larry R.
Purdue Research Foundation
LandOfFree
Monoclonal antibodies specific for neoplasia-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies specific for neoplasia-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies specific for neoplasia-specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3635530